Basic Information
Nimenrix
Regulatory Information
EMEA/H/C/002226
April 20, 2012
February 16, 2012
41
December 16, 2024
Company Information
Belgium
Boulevard de la Plaine 17 1050 Bruxelles
Pfizer Europe MA EEIG
Active Ingredients
Active Substances Detail
Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoidNeisseria meningitidis group C polysaccharide conjugated to tetanus toxoidNeisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoidNeisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid
Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid
Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid
Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid
Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.
Overview Summary
Nimenrix is a vaccine used to protect adults, adolescents and children from the age of 6 weeks against invasive meningococcal disease caused by four groups of the bacterium Neisseria meningitidis (group A, C, W-135, and Y). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood poisoning). The vaccine contains substances from the outer coat of the bacterium N. meningitidis.